New insider activity at 4D Molecular Therapeutics ( (FDMT) ) has taken place on October 27, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics, has recently sold 2,678 shares of the company’s stock, amounting to a total transaction value of $32,136.
Spark’s Take on FDMT Stock
According to Spark, TipRanks’ AI Analyst, FDMT is a Neutral.
The overall stock score is primarily influenced by the company’s financial performance challenges, which are typical for early-stage biotech firms. Despite these challenges, the stock shows strong technical momentum, suggesting positive market sentiment. However, the lack of profitability and absence of dividends weigh down the valuation score.
To see Spark’s full report on FDMT stock, click here.
More about 4D Molecular Therapeutics
YTD Price Performance: 94.51%
Average Trading Volume: 1,303,527
Technical Sentiment Signal: Buy
Current Market Cap: $529.6M